[Practical management of PARP inhibitors: A French DELPHI consensus].
Fiche publication
Date publication
septembre 2022
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel, Pr SCHMITT Antonin
Tous les auteurs :
Selle F, Boffa JJ, Etienne G, Angelergues A, Augereau P, Berton D, Dielenseger P, Fabbro M, Falandry C, Follana P, Gladieff L, Joly F, Kurtz JE, Matta C, Mouret-Reynier MA, Schmitt A, Scotté F, Marjollet C, Floquet A
Lien Pubmed
Résumé
Despite an increasing number of therapeutic indications, there are no specific recommendations regarding the management of PARP inhibitors other than what is specified in the SmPC of each substance. A Delphi French consensus was conducted to establish practical guidelines to meet the needs identified by healthcare professionals and patients.
Mots clés
Breast cancer, Cancer de la prostate, Cancer de l’ovaire, Cancer du pancréas, Cancer du sein, Consensus Delphi, Delphi consensus, Inhibiteurs de PARP, Ovarian cancer, PARP inhibitors, Pancreatic cancer, Prostate cancer
Référence
Bull Cancer. 2022 09 12;: